Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis

Table 3

Subgroup analyses for fibrosis evaluation indicated by the METAVIR fibrosis score system.

Group/subgroup	Weight (%)	Effect size		Heterogeneity for each subgroup
		RR	95% CI	I ^2 (%)
All experiments	100	0.66	(0.47, 0.94)	71	0.001
Animal model
Liver fibrosis/cirrhosis	71.9	0.73	(0.5, 1.07)	74	0.004
Nonalcoholic fatty liver disease	28.1	0.55	(0.33, 0.93)	19	0.29
Animal species
Male	72.1	0.65	(0.4, 1.04)	79	0.0002
Unclear	27.9	0.63	(0.44, 0.91)	0	0.79
Treatment duration (weeks)
≤8	71.9	0.73	(0.5, 1.07)	74	0.004
>8	28.1	0.55	(0.33, 0.93)	19	0.29
Treatment timing
Simultaneous injection at model induction	56.0	0.61	(0.46, 0.81)	0	0.65
Injection after model induction	44.0	0.79	(0.46, 1.35)	81	0.005
Anticoagulation type
Low molecular weight heparin (enoxaparin)	34.5	0.83	(0.5, 1.4)	76	0.04
Antiplatelet agents (aspirin, ticlopidine and cilostazol)	65.5	0.58	(0.37, 0.91)	61	0.03

CI, confidence interval; RR, risk ratio.